Windtree Therapeutics Inc (WINT) Actualités

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”...

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree...

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Evofem Reports Fourth Consecutive Year of Net Sales Growth PR Newswire SAN DIEGO, March 24, 2025 -- 2024 Net...

Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure

WARRINGTON, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India

WARRINGTON, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Windtree Therapeutics, Inc. Announces Reverse Stock Split

WARRINGTON, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree”...

Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference

WARRINGTON, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Form 8-K - Current report

Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline

WARRINGTON, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Form 8-K - Current report